The experience of use of the minocycline at a daily dose of 50 mg and topical therapy in patients with acne vulgaris


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Acne vulgaris is a chronic inflammatory disease, manifested by open or closed comedones and inflammatory skin lesions in the form of papules, pustules, nodes. Objective. Improvement of the effectiveness and safety of the therapy of severe papulopustular acne by inclusion of systemic antibiotic minocycline at a minimal daily dose of 50 mg in combination with topical fixed combination of adapalene+benzoyl peroxide in the treatment regimen in accordance with clinical guidelines. Methods. 20 patients (16 women and 4 men) with severe papulopustular acne aged 14 to 39 years were followed-up. Depending on age, patients were divided into 2 groups: group 1 (n=11) - acne vulgaris (14-24 years old patients), group 2 (n=9) - adult acne (patients over 25 years old). All patients received a course of peroral minolexin (minocycline) at a daily dose of 50 mg for 6-8 weeks, a topical preparation (adaptalen+benzoyl peroxide) and specialized dermatocosmetics (cleansing, moisturizing). As control methods, IGA and HRQOL scales were used, as well as laboratory analysis data (complete blood count, biochemical blood test - ASAT, ALAT, GGTP, ANA). Results. Against the background of the therapy, 7 (64%) patients of the first group achieved complete clearance of the skin - IGA=0,4 (36%) - practically clear skin - IGA<1. In 5 (56%) patients of the second group, complete clearance of the skin was achieved - IGA=0, in 4 (44%) - practically clear skin - IGA<1. According to the HRQOL questionnaire, in patients of first group self-perception indicators improved by 42.7%, emotional sphere indicators - by 37%, social sphere ones - by 38.7%, acne symptoms - by 44%. In patients of the second group, self-perception indicators improved by 53%, emotional sphere indicators - by 41.7%, social sphere indicators - by 47.4%, acne symptoms - by 51.6%. In general, according to the HRQOL scale, there was an improvement in patients of the first group by 40.5%, in patients of the second group by 48.6%. During the whole follow-up period, there were no adverse events requiring cancellation or correction of the prescribed therapy. Conclusion. Minolexin (minocycline) at a daily dose of 50 mg is a highly effective and safe drug for the treatment of patients with severe papulopustular acne and can be recommended for widespread use in clinical practice, including in combination with topical therapy with a fixed combination of adapalene+benzoyl peroxide.

Full Text

Restricted Access

About the authors

L. S Kruglova

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

Email: kruglovals@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Cosmetology

N. V Gryazeva

Central State Medical Academy of Department for Presidential Affairs of the Russian Federation

References

  1. Maddin W.S., LandeHs I.D., Poulin Y., et al. Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg. 2000;4(Suppl. 1):2-13
  2. Vos T, Flaxman A.D, Naghaviet М., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. doi: 10.1016/S0140-6736(12)61729-2.
  3. Wilmer E.N., Gustafson C.J., Ahn C.S., et al. Most Common Dermatologic Conditions Encountered by Dermatologists and Nondermatologists. Cutis. 2014;94:295-92
  4. Del Rosso J.Q., Kircik L.H. The Sequence of Inflammation, Relevant Biomarkers, and the Pathogenesis of Acne Vulgaris: What Does Recent Research Show and What Does It Mean to the Clinician? J Drugs Dermatol. 20l3:l2(Suppl 8):s109-s115.
  5. Levin J. The Relationship of Proper Skin Cleansing to Pathophysiology, Clinical Benefits, and the Concomitant Use of Prescription Topical Therapies in Patients With Acne Vulgaris. Dermatol Clin. 2016;34:133-45. Doi: 10.1016/j. det.2015.11.001.
  6. Beylot C, Auffret N., Poli F, et al. Propionibacterium Acnes: An Update on Its Role in the Pathogenesis of Acne. J Eur Acad Dermatol Venerol. 2014;28:271-78. doi: 10.1111/jdv.12224.
  7. Nast A., Dreno B., Bettoli V., et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. JEADV 2012;26(Suppl. 1):1-29. doi: 10.1111/j.1468-3083.2011.04374.x.
  8. Рахманова С.Н., Юцковский А.Д., Накорякова Л.Ф. Чувствительность микрофлоры кожи к антибиотикам у пациентов с угревой болезнью. Тихоокеанский медицинский журнал. 2009;1:92-4
  9. Thiboutot D, Gollnick H., Bettoli V., et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009;60:1-50. doi: 10.1016/j.jaad.2009.01.019.
  10. Lee Y.H, Liu G., Thiboutot D.M., et al. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol. 2014;71(1):70-6. doi: 10.1016/j.jaad.2014.02.031.
  11. Chopra I., Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65:232-60. Doi: 10.1128/ MMBR.65.2.232-260.2001.
  12. Garner S.E., Eady E.A., Popescu C., Newton J., Li W.A. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2003;CD002086. doi: 10.1002/14651858. CD002086.
  13. Giuliani F, Hader W., Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol. 2005;78:135-43. Doi: 10.1189/ jlb.0804477.
  14. Popovic N., Schubart A., Goetz B.D., et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 2002;51:215-23. doi: 10.1002/ana.10092.
  15. Song Y, Wei E.Q., Zhang W.P, et al. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. NeuroReport. 2004;15:2181-84. doi: 10.1097/00001756200410050-00007.
  16. Chen M., Ona VO., Li M., et al. Minocycline inhibits caspase - and caspase -3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6:797-801. doi: 10.1038/77528.
  17. Domerq M., Matute C. Neuroprotection of by tetracyclines. Trends Pharmacol Sci. 2004;25:609 12. doi: 10.1016/j.tips.2004.10.001
  18. Garner S.E., Eady A., Bennett C., et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012;8:CD002086. doi: 10.1002/14651858.CD002086.pub2.
  19. Клинические рекомендации. Акне вульгарные. Российское общество дерматовенерологов и косметологов. 2020. [Clinical recommendations. Acne is vulgar. Russian Society of Dermatovenerologists and Cosmetologists. 2020. (In Russ.)].
  20. Allen B.S., Smith J.G. Jr. Various parameters for grading acne vulgaris Arch Dermatol. 1982;118:23-5.
  21. Girman C.J., Hartmaier S., Thiboutot D., et al. Evaluating healthrelated quality of life in patients with facial acne: development of a selfadministered questionnaire for clinical trials. Qual Life Res. 1996:5(5):4-1-90. Doi: 10.1007/ BF00540020.
  22. Sardana K., et al. Cross-sectional Pilot Study of Antibiotic Resistance in Propionibacterium Acnes Strains in Indian Acne Patients Using 16S-RNA Polymerase Chain Reaction: A Comparison Among Treatment Modalities Including Antibiotics, Benzoyl Peroxide, and Isotretinoin. Indian J Dermatol. 2016:61(1):45-52. doi: 10.4103/00195154.174025.
  23. Leyden J.J., Del Rosso J.Q. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol. 2011:4:40-7.
  24. Torok H.M. Extended-release formulation of minocycline in the treatment of moderate-to-severe acne vulgaris in patients over the age of 12 years. J Clin Aesthet Dermatol. 2013; 6:19-22.
  25. Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013:17:114-22. doi: 10.2310/7750.2012.12026.
  26. Stewart D., Torok H., Weiss J., Plott R. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006;78(Suppl. 4):11-2.
  27. Torok H.M. Extended-release Formulation of Minocycline in the Treatment of Moderate-to-severe Acne Vulgaris in Patients over the Age of 12 Years. J Clin Aesthet Dermatol. 2013:6:19-22.
  28. Ochsendorf F. Systemic antibiotic therapy of acnevulgaris. J Dtsch Dermatol Ges. 2006;4:828 41. doi: 10.1111/j.1610-03-7.2006.06053.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies